Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience

BACKGROUND: Despite the wide spread use of trastuzumab in human epidermal growth factor receptor 2 (HER2) overexpressing metastatic gastric cancer patients, its optimal duration of administration beyond first-line disease progression is unknown. In HER2 overexpressing metastatic breast cancer, trast...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Gastrointest Oncol
Auteurs principaux: Al-Shamsi, Humaid O., Fahmawi, Yazan, Dahbour, Ibrahim, Tabash, Aziz, Rogers, Jane E., Mares, Jeannette Elizabeth, Blum, Mariela A., Estrella, Jeannelyn, Matamoros, Aurelio, Sagebiel, Tara, Devine, Catherine E., Badgwell, Brian D., Lin, Quan D., Das, Prajnan, Ajani, Jaffer A.
Format: Artigo
Langue:Inglês
Publié: AME Publishing Company 2016
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4963369/
https://ncbi.nlm.nih.gov/pubmed/27563438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.06.16
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires